Esperion Therapeutics, Inc.

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

HLS Therapeutics Inc.HLS · PharmaceuticalsEtobicoke, Canada

64% matchPublic

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

Sarepta Therapeutics, Inc. operates as a biopharmaceutical firm with products already available on the market. Its primary objective is the research and advancement of genetic treatment modalities, encompassing RNA-targeted therapeutics and gene therapies, specifically for the management of rare diseases. The company's commercial offerings include EXONDYS 51, an injectable medication prescribed for Duchenne muscular dystrophy (DMD) patients whose genetic mutation in the dystrophin gene is responsive to exon 51 skipping. Similarly, VYONDYS 53 is provided for individuals with DMD who can benefit from exon 53 skipping. Sarepta is also actively developing several investigational therapies: AMONDYS 45, a product candidate that utilizes phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to bypass exon 45 of the dystrophin gene. SRP-5051, a peptide-conjugated PMO engineered to bind to exon 51 of dystrophin pre-mRNA. SRP-9001, a gene therapy initiative focused on micro-dystrophin for DMD. SRP-9003, a gene therapy program targeting limb-girdle muscular dystrophies. The company has established collaborative relationships with various partners, including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Sarepta was incorporated in 1980 and maintains its corporate headquarters in Cambridge, Massachusetts.

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.